ReviewArthritis & rheumatology (Hoboken, N.J.)2025
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis.
Review in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Bone Mineral Density Loss After Kidney Transplantation: Metabolic Determinants, Diagnostic Approaches, and Preventive Strategies.Kidney international reports · 2026Review
- Plant-based macronutrients and micronutrients in combating osteoporosis: research insights and molecular pathways.RSC advances · 2026Review
- Development of a Machine Learning-Based Triage Score for Medication-Related Osteonecrosis of the Jaw in Osteoporosis Patients Undergoing Tooth Extraction.Diagnostics (Basel, Switzerland) · 2026Article
- Denosumab in osteoarthritis: from mechanism to clinical translation.Frontiers in immunology · 2026Article
- Molecular Mechanisms and Therapeutic Potential of Puerariae Lobatae Radix in Bone Metabolism: A Comprehensive Review.Drug design, development and therapy · 2026Review
- Exploring the Role ofOrthopedic research and reviews · 2026Review
- Postmenopausal Osteoporosis: From Molecular Pathways to Therapeutic Targets-A Mechanism-to-Practice Framework Integrating Pharmacotherapy, Fall Prevention, and Adherence into Patient-Centered Care.Journal of clinical medicine · 2025Review
- ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short- and long-term risks that, coupled with their benefits and other unique characteristics, influence consideration for at least periodic discontinuation. Bisphosphonates retain their effects even after discontinuation due to their prolonged skeletal retention, whereas denosumab discontinuation is associated with a rapid rebound in bone turnover and increased fracture risk. There is controversy about how, when, and why to potentially stop these agents. We discuss both permanent and temporary discontinuation of long-term treatment with bisphosphonates and denosumab. We focus on the reasons and timing for discontinuation as well as strategies to mitigate future fracture risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.